Skip to main content

Step-wise Procedure to Calculate Confirmation Cut Point for Anti-Drug Antibody Assay


The cut-point of the assay is the level of response of the assay that defines the sample response as positive or negative. Establishing the appropriate cut-point is critical to minimizing the risk of false-negative results. The confirmation cut points are determined by assaying a set of approximately 50 drug-naive individual serum samples over three days by two analysts for a total of six runs. Here, we describe the stepwise procedure to calculate the statistical cut point using the parametric and robust parametric method. 

Steps for estimating confirmation cut points

1) Compile the data from 50 drug-naive individuals assayed by two analysts over 3 days for a total of six days. (See template below) 

2) Compute the % Signal Inhibition or % Immunodepletion from the assay signal generated in the presence and absence of the drug.  

3) Use the box plot analysis in JMP to identify and exclude outliers. 

4) Use the Shapiro-Wilk Test for the test of homogeneity or normality. The data is normally distributed when the p-value for the Shapiro-Wilk Test is less than 0.05. Use the nonparametric method for the data that are not normally distributed.

5) Perform ANOVA analysis (Oneway ANOVA in JMP software)  to compare the mean and variances among six runs. 
   

6) Use the Parametric method for the data sets 
         -when the pooled the %SI data is normally distributed   

The formula for parametric cut point with a 1% false-positive rate
        
          Confirmation Cut Point = Mean (Normalized) + 2.33 X Standard Deviation

7) Evaluate the cut point using Robust Parametric Method for the data sets with higher outliers

         Confirmation Cut Point = Median (Normalized) + 2.33 X (1.45 X Median Absolute Deviation)


Template for Data Complilation
Cutpoint 
Run 
 Day   Analyst A/B
 Plate 
NC-signal 
 %CV
 Drug 
Naive 
Individual ID 
Screen Sample Signal
(S)
 Confrm 
Sample Signal
(C)
 100% (1-C/S)
         


Reference 
Shankar et al 2008
FDA Guidance on ADA assay 2019

Comments

Popular posts from this blog

MCQs on Neisseria gonorrhoeae and Neisseria meningitidis: Medical microbiology

                                                       Multiple Choice Questions on Neisseria species (Gram-negative cocci) 1) A 19-year-old female college freshman, presented to the university health center with a severe headache, fever, and a stiff neck. She lived in a dormitory and was active in various social activities. She had received all her childhood vaccinations but had not received a booster for the meningococcal vaccine recommended before college entry. Clinical Presentation: On day 1, the patient experienced a sudden onset of fever (39.5°C or 103.1°F), severe headache, nausea, and vomiting. She also noticed a rash on her trunk and legs. Over the next two days, her symptoms deteriorated further, leading to photophobia and altered mental status. Concerned, her roommates brought her to the university health center. Physical Examinati...

Multiple Choice Questions (MCQs) on Diabetes Mellitus: Pathogenesis, Diagnosis and Treatment

                                        MCQs on Diabetes mellitus 1) Diabetes mellitus is a disorder characterized by hyperglycemia.  Which of the following is not the common characteristic features of type 2 diabetes mellitus ? a) Impaired insulin secretion b) Increased Insulin resistance  c) Diabetic ketoacidosis d) Excessive hepatic glucose production 2) Which of the following are the characteristic features of type 1 diabetes mellitus? a) Type 1 diabetes is caused by an absolute deficiency of insulin. b) Type 1 diabetes is associated with the autoimmune destruction of beta cells.  c) Patients with  uncontrolled type 1 diabetes present with diabetic ketoacidosis d) All of the above   3) Which of the following serum measurements are not used for the diagnosis of diabetes mellitus? a) Fasting blood glucose d) Postprandial blood glucose  c) Insulin ...

Pentose Phosphate Pathway: Source of NADPH for Reductive Biosynthesis (Biochemistry)

Introduction to Pentose Phosphate Pathway The pentose phosphate pathway ( Hexose monophosphate pathway ) is the metabolic pathway that occurs in the cytosol and generates NADPH (nicotinamide adenine dinucleotide phosphate) which is utilized in various biosynthetic pathways. This pathway can be broadly classified into two phases i.e oxidative phase and non-oxidative phase.  In the oxidative stage of the pentose phosphate pathway, the glucose-6-phosphate is converted to five carbon ribulose-5 phosphate with generation of NADPH.  During the non-oxidative stage, the interconversion of pentose sugars and hexose sugars is catalyzed by isomerases and aldolases. The fate of these reversible steps depends on the anabolic and energy status of the cells.  The two primary functions of the pentose phosphate pathway are ; a) Provide NADPH (a coenzyme) for biosynthetic pathways b) Provide pentose sugars for nucleotides (DNA and RNA) synthesis Two phases of Pentose phosphat...